Royal Bank of Canada’s Vivos Therapeutics VVOS Stock Holding History

Royal Bank of Canada’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	4	–	–	﹤0.01%	7854
2026 Q1	$0	Hold	4	–	–	﹤0.01%	7741
2025 Q4	$0	Hold	4	–	–	﹤0.01%	7686
2025 Q3	$0	Hold	4	–	–	﹤0.01%	7566
2025 Q2	$0	Sell	4 -18,000	-100%	-$45.4K	﹤0.01%	7381
2025 Q1	$51K	Buy	18,004 +18,000	+450,000%	+$70.7K	﹤0.01%	5569
2024 Q4	$0	Hold	4	–	–	﹤0.01%	7288
2024 Q3	$0	Sell	4 -3	-43%	-$8	﹤0.01%	7508
2024 Q2	$0	Hold	7	–	–	﹤0.01%	7585
2024 Q1	$0	Hold	7	–	–	﹤0.01%	7654
2023 Q4	$0	Sell	7 -11	-61%	-$94	﹤0.01%	7631
2023 Q3	$0	Sell	18 -36	-67%	-$272	﹤0.01%	7653
2023 Q2	$1K	Buy	54 +41	+315%	+$402	﹤0.01%	7096
2023 Q1	$0	Buy	13 +9	+225%	+$197	﹤0.01%	7527
2022 Q4	$0	Sell	4 -683	-99%	-$9.99K	﹤0.01%	7772
2022 Q3	$11K	Buy	687 +677	+6,770%	+$20.6K	﹤0.01%	6399
2022 Q2	$0	Buy	10 +4	+67%	+$166	﹤0.01%	7751
2022 Q1	$0	Hold	6	–	–	﹤0.01%	8047
2021 Q4	$0	Sell	6 -21	-78%	-$1.69K	﹤0.01%	7920
2021 Q3	$3K	Buy	+27	New	+$2.84K	﹤0.01%	7280

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Royal Bank of Canada's VVOS Position: Q2 2026 in Review

Royal Bank of Canada held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7854.

Royal Bank of Canada first reported a position in VVOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $51K in Q1 2025. 22 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Royal Bank of Canada held 4 shares of Vivos Therapeutics worth $0 as of Q2 2026.
Royal Bank of Canada left its Vivos Therapeutics share count unchanged in Q2 2026.
Vivos Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7854 holding.
Royal Bank of Canada first reported a position in Vivos Therapeutics in Q3 2021 and has held it in 20 quarters since.
Royal Bank of Canada's Vivos Therapeutics position peaked at $51K in Q1 2025.
22 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.